Action Pharma A/S

May 2012: Action Pharma has sold the phase II project AP214 targeting prevention of acute kidney injury associated with major cardiac surgery in patients at increased risk to Abbott for USD 110 million. The transaction takes up a 10th place globally among published up-front deals in the period 2007-2012.

Read the press release


Sten Verland


Mobile: +45 24 22 19 69
Email Click here to contact
Action Pharma Logo